| Schedule of segment information |
Year Ended December 31, 2025 | | Benchtop Laboratory Equipment | | | Bioprocessing Systems | | | Corporate | | | Consolidated | | United States revenue | | $ | 3,753,800 | | | $ | 424,400 | | | $ | - | | | $ | 4,178,200 | | Foreign revenue | | | - | | | | 875,600 | | | | - | | | | 875,600 | | Total Revenue | | $ | 3,753,800 | | | $ | 1,300,000 | | | $ | - | | | $ | 5,053,800 | | | | | | | | | | | | | | | | | | | Segment Significant Expenses: | | | | | | | | | | | | | | | | | Cost of revenues | | | 2,677,500 | | | | 1,073,200 | | | | | | | | 3,750,700 | | Compensation and other personnel expenses | | | 709,700 | | | | 3,964,300 | | | | 388,000 | | | | 5,062,100 | | Other expenses | | | 774,100 | | | | 1,785,800 | | | | 961,000 | | | | 3,520,900 | | Depreciation and Amortization | | | 45,600 | | | | 564,400 | | | | - | | | | 610,000 | | Segment Loss From Operations | | $ | (453,100 | ) | | $ | (6,087,700 | ) | | $ | (1,349,000 | ) | | $ | (7,889,900 | ) | | | | | | | | | | | | | | | | | | Assets | | | 3,392,000 | | | | 3,510,600 | | | | 5,705,000 | | | | 12,607,600 | | Long-Lived Asset Expenditures | | | 16,300 | | | | 46,900 | | | | - | | | | 63,200 | |
Year Ended December 31, 2024 Adjusted | | Benchtop Laboratory Equipment | | | Bioprocessing Systems | | | Corporate | | | Consolidated | | United States revenue | | $ | 3,107,300 | | | $ | 563,900 | | | $ | - | | | $ | 3,671,200 | | Foreign revenue | | | - | | | | 1,125,900 | | | | - | | | | 1,125,900 | | Total revenue | | | 3,107,300 | | | | 1,689,800 | | | | - | | | | 4,797,100 | | | | | | | | | | | | | | | | | | | Segment Significant Expenses: | | | | | | | | | | | | | | | | | Cost of revenues | | | 2,076,700 | | | | 713,800 | | | | - | | | | 2,790,500 | | Compensation and other personnel expenses | | | 900,100 | | | | 3,899,000 | | | | 418,700 | | | | 5,217,800 | | Other expenses | | | 916,700 | | | | 2,219,800 | | | | 1,118,000 | | | | 4,254,500 | | Depreciation and Amortization | | | 85,000 | | | | 665,700 | | | | - | | | | 750,700 | | Segment Loss From Operations | | | (871,100 | ) | | | (5,808,500 | ) | | | (1,536,800 | ) | | | (8,216,400 | ) | | | | | | | | | | | | | | | | | | Assets | | | 5,751,500 | | | | 3,824,300 | | | | 1,985,000 | | | | 11,560,800 | | Long-Lived Asset Expenditures | | | 75,900 | | | | 23,000 | | | | - | | | | 98,900 | |
|
| Schedule of reconciliation of the company's consolidated segment incomed loss |
| | Year Ended | | | Year Ended | | | | December 31, 2025 | | | December 31, 2024 | | | | Revenue (a) | | | Long-Lived Assets | | | Revenue (a) | | | Long-Lived Assets | | United States | | $ | 4,178,200 | | | $ | 969,400 | | | $ | 3,671,200 | | | $ | 1,157,700 | | All Other Foreign Countries | | | 621,400 | | | | - | | | | 563,100 | | | | - | | Germany | | | 254,200 | | | | 631,300 | | | | 562,800 | | | | 738,300 | | Total | | $ | 5,053,800 | | | $ | 1,600,700 | | | $ | 4,797,100 | | | $ | 1,896,000 | |
Year ended December 31, 2025 | | Benchtop Laboratory Equipment | | | Bioprocessing Systems | | | Corporate | | | Consolidated | | Loss from Operations | | $ | (412,900 | ) | | $ | (6,128,000 | ) | | $ | (1,349,000 | ) | | $ | (7,889,900 | ) | Other income (expense), net | | | 5,263,300 | | | | 736,600 | | | | 114,300 | | | | 6,114,200 | | Loss from operations before discontinued operations and income taxes | | $ | 4,850,400 | | | $ | (5,391,400 | ) | | $ | (1,234,700 | ) | | $ | (1,775,700 | ) |
Year ended December 31, 2024 | | Benchtop Laboratory Equipment | | | Bioprocessing Systems | | | Corporate | | | Consolidated | | Loss from Operations | | $ | (871,100 | ) | | $ | (5,808,500 | ) | | $ | (1,536,800 | ) | | $ | (8,216,400 | ) | Other income (expense), net | | | (3,600 | ) | | | 27,700 | | | | 168,700 | | | | 192,800 | | Loss from operations before discontinued operations and income taxes | | $ | (874,700 | ) | | $ | (5,780,800 | ) | | $ | (1,368,100 | ) | | $ | (8,023,600 | ) |
|